Ask AI
Helena Yu

Helena Yu, MD

Research Director
Associate Attending
Thoracic Oncology Service
Memorial Sloan Kettering Cancer Center
New York, New York

Explore Activities by Helena Yu

Title
Format
Credit Type
Credits
New Frontiers in Advanced EGFR-Mutated NSCLC Therapy: Targeting HER3 With Novel Agents

Content Format:

Slideset

Credit Type:

--

Credits:

--
New Frontiers in Advanced EGFR-Mutated NSCLC Therapy: Targeting HER3 With Novel Agents

Content Format:

Text Module

Credit Type:

AMA

Credits:

0.75
Transforming Precision Lung Cancer Care: Expert Guidance on HER2-, HER3-, TROP2-, and B7-H3–Targeted ADCs

Content Format:

Video

Credit Type:

AMA | EBAC®

Credits:

1.50
Transforming Precision Lung Cancer Care: Expert Guidance on HER2-, HER3-, TROP2-, and B7-H3-Targeted ADCs

Content Format:

Credits Only

Credit Type:

AMA | EBAC®

Credits:

1.50
Antibody–Drug Conjugates in EGFR-Mutated NSCLC

Content Format:

Slideset

Credit Type:

--

Credits:

--
Mapping TROP-2–Targeted ADCs Into the NSCLC Treatment Landscape

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
TROP-2–Targeted ADCs for NSCLC: ​Integrating a New Therapeutic Option

Content Format:

Video

Credit Type:

AMA | EBAC®

Credits:

1.25
Latest Therapeutic Advancements in Targeting TROP-2 in NSCLC

Content Format:

Slideset

Credit Type:

--

Credits:

--
TROP-2–Targeted ADCs for NSCLC: Integrating a New Therapeutic Option

Content Format:

Credits Only

Credit Type:

AMA | EBAC®

Credits:

1.50
Optimizing NSCLC Treatment: Potential of ADCs Targeting HER2, HER3, and TROP-2

Content Format:

Video

Credit Type:

AMA

Credits:

1.50
A Year in Review: ADCs Targeting HER3 in NSCLC

Content Format:

Slideset

Credit Type:

--

Credits:

--
Unpacking the Potential of HER3-Targeted Therapy in NSCLC

Content Format:

Podcast Episodes

Credit Type:

--

Credits:

--
Current Considerations for Adverse Event Management With HER3-Directed Agents

Content Format:

Podcast Episodes

Credit Type:

--

Credits:

--
Recent Advances in ADCs and Rationale for HER3 as a Target in Lung Cancer

Content Format:

Podcast Episodes

Credit Type:

--

Credits:

--
2023 World Conference on Lung Cancer: Expert Perspectives on Key Studies

Content Format:

Text Module

Credit Type:

AAPA | ACPE | AMA | ANCC

Credits:

1.50
Congress to Clinic: Continual Evolution of HER3-Targeting in NSCLC With Expert Perspectives on Clinical Advances and Practical Application

Content Format:

Slideset

Credit Type:

--

Credits:

--
HER3-Targeted Antibody–Drug Conjugates for Lung and Breast Cancers: Where We Are Today

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
2023 World Conference on Lung Cancer Preview: Experts Choose the Top Abstracts

Content Format:

Conference Coverage

Credit Type:

--

Credits:

--
From Congress to Clinic: A Post-JSMO Update on Novel Antibody–Drug Conjugates and Other Agents Targeting HER3 in NSCLC

Content Format:

Video

Credit Type:

AMA

Credits:

1.00
FAQs: Novel Antibody–Drug Conjugates and Other Agents Targeting HER3 in NSCLC

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Current Investigational Treatments Targeting HER3 in EGFR-Positive Post-TKI NSCLC

Content Format:

Slideset

Credit Type:

--

Credits:

--
Expert Think Tank: Lung Cancer Experts Discuss Current Standard of Care and Ongoing Challenges in the Care of Patients With EGFR-Mutated NSCLC

Content Format:

Text Module

Credit Type:

ACPE | AMA | ANCC

Credits:

1.25
Expert Think Tank: Current Standard of Care and Ongoing Challenges in the Care of Patients With EGFR-Mutated NSCLC

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Resources to Improve the Care of Patients With NSCLC and EGFR Mutations

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Antibody–Drug Conjugates in Lung Cancer Care

Content Format:

Multimedia

Credit Type:

ACPE | AMA | ANCC

Credits:

0.25
Antibody–Drug Conjugates in Lung Cancer Care

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Mechanisms of Resistance to EGFR TKI Therapy in Advanced Lung Cancer

Content Format:

Multimedia

Credit Type:

ACPE | AMA | ANCC

Credits:

0.25
Mechanisms of Resistance to EGFR TKI Therapy in Advanced Lung Cancer

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Treatment for EGFR-Mutant Lung Cancer After Progression on EGFR TKI

Content Format:

Multimedia

Credit Type:

ACPE | AMA | ANCC

Credits:

0.25
Treatment for EGFR-Mutant Lung Cancer After Progression on EGFR TKI

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Role of HER3 in Lung Cancer

Content Format:

Multimedia

Credit Type:

ACPE | AMA | ANCC

Credits:

0.25
Role of HER3 in Lung Cancer

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Congress to Clinic: Post-ELCC Updates on Antibody–Drug Conjugates in NSCLC

Content Format:

Podcast Episodes

Credit Type:

--

Credits:

--
Congress to Clinic: Post-ELCC Updates on Antibody–Drug Conjugates in NSCLC

Content Format:

Multimedia

Credit Type:

AMA

Credits:

1.00
My Thoughts on When to Consider ADCs for Today’s Patients With Advanced NSCLC

Content Format:

Clinical Thought

Credit Type:

--

Credits:

--
Express PointsCongress to Clinic: Post-ELCC Updates on Antibody–Drug Conjugates in NSCLC

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Activity of ADCs in Clinical Trials for Lung Cancer: Anti-HER2/HER3 ADCs

Content Format:

Slideset Download

Credit Type:

--

Credits:

--
Practical Insights on Key Data From ESMO 2020 Informing Precision Medicine in NSCLC

Content Format:

Podcast Episodes

Credit Type:

--

Credits:

--
Data From ESMO 2020 Informing Precision Medicine in NSCLC: Podcast Pearls

Content Format:

PDF

Credit Type:

--

Credits:

--
Shared Decision-Making and the Current Landscape of Checkpoint Inhibitor Therapy in Metastatic NSCLC

Content Format:

Slideset Download

Credit Type:

--

Credits:

--